Trial Profile
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics
- Sponsors Seagen; Seattle Genetics
- 04 Jan 2017 Results analysing maximum tolerated dose(MTD), pharmacokinetics and antitumor activity published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 07 Oct 2013 Final results will be presented at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research according to an Oncothyreon media release. Results were also reported in the media release.
- 30 May 2013 Results reported in an Oncothyreon and Array BioPharma media release.